Gastroenterology
Dyspepsia
81
Pipeline Programs↗
18
Active Trials↗
32
Companies Involved↗
Dyspepsia is a moderately active landscape with 81 programs across 32 companies. The most active players are Abide Therapeutics, GSK, Ironwood Pharmaceuticals, Inc.. 21 therapies are approved with 27 more in late-stage development.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical16
Phase 15
Phase 212
Phase 327
Analysis
Trial Status
117
clinical trials
Completed67 · 57%
Unknown status21 · 18%
Recruiting10 · 9%
Terminated9 · 8%
Active, not recruiting4 · 3%
Not yet recruiting3 · 3%
Other3 · 3%
Clinical Trials
Trial Activity
117 trials
Ketotifen for Children With Functional Dyspepsia in Association With Duodenal Eosinophilia
Recruiting·—·Phase 3·NCT02484248·40 enrolled
Effects of Cognitive Behavioral Therapy Through a Mobile App on Patients With Refractory Functional Dyspepsia
Recruiting·—·N/A·NCT06756139·88 enrolled
Page 1 of 8
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)